TP53 and cancer: However, in cancer cells, the G1/S checkpoint control appears to be lost despite the fact that IP3R inhibition still leads to activation of AMPK, implying defects in the mechanisms linking AMPK to the G1/S checkpoint arrest, for example, mutations impairing p53 activity or hyperactivating CDKs.